Remdesivir, a nucleotide analog antiviral drug in development by Gilead, is effective against EBOV (EC50 = 70-140 nM) and other filoviruses (EC50 = 0.019 in cell-based assays) -1.48 uM) exhibited antiviral activity; inhibited EBOV replication and protected 100% of EBOV-infected animals from lethal disease, improving clinical disease signs and pathophysiological indicators. Remdesivir is still an experimental drug in clinical trials.
Remdesivir currently has two clinical trials, both sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) | National Institutes of Health Clinical Center (CC):
Against the Ebola virus. The start date is November 20, 2018, and it is currently Phase II/Phase III.
Against persistent Ebola. The start date is June 28, 2016, and it is currently Phase II.
Remdesivir is being used in clinical trials to treat Ebola virus infection with very good results. Subsequent studies have found that Remdesivir is not only effective against filoviruses such as Ebola virus, but also has inhibitory effects on respiratory syncytial virus, coronavirus, Nipah virus and Hendra virus. In addition, in vitro cell experiments and animal model experiments confirmed that Remdesivir has antiviral effects on both atypical pneumonia coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Although there is currently no antiviral data showing the activity of remdesivir against 2019-nCoV, the drug has not been licensed or approved in any part of the world, and its safety and efficacy have not been proven; however, the drug targets SARS-CoV and The effective data of MERS-CoV gives us a reference for the treatment of novel viruses.
Since February 3, the China-Japan Friendship Hospital has led a randomized, double-blind, controlled phase III clinical study of remdesivir in the treatment of novel coronavirus in the epidemic area of Wuhan, and plans to enroll 270 patients with mild to moderate novel coronavirus pneumonia For those infected with the new coronavirus in Wuhan, the experiment will end on April 27.
Post time: Jan-22-2022